United Kingdom

People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

9:00pm BST
Change (% chg)

$1.40 (+0.61%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Mulligan, Richard 

Dr. Richard C. Mulligan, Ph.D. is an Independent Director of Biogen Inc. Dr. Mulligan has served as one of our directors since 2009. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. He also currently serves as a Portfolio Manager at Icahn Capital LP, a position held since March 2017. Prior to Harvard, he was a Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP, a registered investment advisor, from 2013 to 2016. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981. Dr. Mulligan has scientific expertise in the areas of molecular biology, genetics, gene therapy and biotechnology, as well as extensive experience within the healthcare industry, including overseeing the operations and research and development of healthcare companies.

Basic Compensation

Total Annual Compensation, USD 151,000
Restricted Stock Award, USD 269,479
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 420,479

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --